SCHEMBL6462050

SCHEMBL6462050

CC(C)(c1nc(-c2ccccc2)c(CC(=O)Cl)s1)c1c(Cl)cc(-n2ncc(=O)[nH]c2=O)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 8/20 0.41
ABCB11 O95342 1/20 0.41
THRB P10828 6/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
NPSR1 Q6W5P4 3/20 0.37
MAPT P10636 2/20 0.37
RAB9A P51151 2/20 0.37
RXFP1 Q9HBX9 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
NPC1 O15118 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR1I2 O75469 1/20 0.35
THRA P10827 2/20 0.35
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762275 0.94 KDM4E (0.43) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6453803 0.89 P2RX7 (0.39) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6455333 0.88 P2RX7 (0.42) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL7142482 0.87 P2RX7 (0.38) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6459750 0.86 P2RX7 (0.41) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6462754 0.85 P2RX7 (0.41) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6457792 0.83 HRH3 (0.37) P2RX7ABCB11THRBALDH1A1THRA
SCHEMBL5758791 0.83 P2RX7 (0.40) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6459744 0.82 MEN1 (0.39) P2RX7ABCB11THRBMEN1KMT2A
SCHEMBL6459898 0.82 THRB (0.39) P2RX7ABCB11THRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed
EP-0987265-A1 Interleukin-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST P2RX7 880/4885ABCB11 2670/4885THRB 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.